Eli Lilly and Company’s (LLY) Buy Rating Reiterated at Guggenheim

Eli Lilly and Company (NYSE:LLY – Get Free Report)‘s stock had its “buy” rating restated by Guggenheim in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $936.00 price target on the stock. Guggenheim’s price target would suggest a potential upside of 22.61% from the company’s previous close. LLY […]

Leave a Reply

Your email address will not be published.

Previous post Basel Medical Group (NASDAQ:BMGL) Lowered to Sell Rating by Wall Street Zen
Next post Intapp (NASDAQ:INTA) Downgraded by Wall Street Zen to “Buy”